Ropinirole hydrochloride may attenuate the disease progression of ALS

Keio University Hospital

Keio University School of Medicine

K Pharma, Inc.

In a new clinical trial (ROPALS trial), researchers from Keio University have found a novel drug to be safe and effective for treating amyotrophic lateral sclerosis

Tokyo, Japan – Amyotrophic lateral sclerosis (ALS) is a deadly neurodegenerative disease with no known treatment. In a new randomized clinical Phase I/IIa trial, researchers from Keio University treated ALS patients with ropinirole, a drug often used to treat Parkinson's disease. After a period of 1 year, they found the drug to be safe and, most importantly, to have a significant effect in functional and survival outcomes, slowing the progression of the disease.

For further information, please refer to the following PDF file.

Ropinirole hydrochloride may attenuate the disease progression of ALS.pdf